




# Bell Potter Healthcare Conference

November 2024

NASDAQ: TLX

ASX: TLX



Credit: UCLA expanded access program

# Disclaimer

This presentation should be read together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website.

The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this presentation are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this presentation, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in this presentation.

This presentation may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Telix’s actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

This presentation also contains estimates and other statistical data made by independent parties and by Telix relating to market size and other data about its industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of Telix’s future performance and the future performance of the markets in which it operates are necessarily subject to a high degree of uncertainty and risk.

Telix’s lead imaging product, gallium-68 (<sup>68</sup>Ga) gozetotide injection (also known as <sup>68</sup>Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA), by the Australian Therapeutic Goods Administration (TGA), and by Health Canada. No other Telix product has received a marketing authorisation in any jurisdiction.

This presentation has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals® and Illuccix® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.



# Telix: A global leader in theranostics

Therapeutics-led, with a commitment to precision oncology



**Industry-leading,  
late-stage  
therapeutic pipeline**

Highly differentiated assets in urology, neuro-oncology and musculoskeletal cancers, with **multiple clinical milestones ahead**



**Precision medicine  
portfolio driving near-  
term revenue growth  
opportunities**


**Illuccix® Q3 revenue US\$135M up  
51% YOY<sup>1</sup>**, opportunity to build with  
Zircaix®<sup>2</sup>, new PSMA<sup>3</sup> imaging product  
and Pixclara®<sup>4</sup>



**World-class supply  
chain and  
manufacturing**

Expanding in-house manufacturing  
capacity and capability, **a key source  
of competitive advantage**

**See it. Treat it.**




1. Telix ASX disclosure 17 October 2024.
2. Zircaix®: TLX250-CDx for kidney cancer imaging, brand name subject to final regulatory approval.
3. Prostate-specific membrane antigen.
4. Pixclara®: TLX101-CDx for glioma imaging, brand name subject to final regulatory approval.


\*Images from STARLITE-2 study.  
Credit: Memorial Sloan Kettering Cancer Center  
Patient representative scans - individual results may vary.

# Delivering a rapidly growing market opportunity

Global capabilities and capacity for Telix, our partners and patients








### Global radiopharma development and delivery



# Commitment to precision oncology

## An expanding commercial-stage “theranostic” imaging portfolio

	TARGETING AGENT	ISOTOPE	PRE-CLINICAL	PHASE I	PHASE II	PHASE III	COMMERCIAL
Prostate PSMA <sup>1</sup>	Small molecule	<sup>68</sup> Ga	 Illuccix® ( <sup>68</sup> Ga-PSMA-11)				
	Small molecule	<sup>68</sup> Ga	 TLX007-CDx				
Kidney + other CAIX <sup>2</sup>	Antibody	<sup>89</sup> Zr	 TLX250-CDx, Zircaix® <sup>4</sup> ( <sup>89</sup> Zr-girentuximab)				
Brain LAT1 & LAT2 <sup>3</sup>	Small molecule	<sup>18</sup> F	 TLX101-CDx, Pixclara® <sup>4</sup> ( <sup>18</sup> F-floretyrosine)				
Musculo-skeletal	Antibody	<sup>99m</sup> Tc	 TLX66-CDx ( <sup>99m</sup> Tc-besilesomab, Scintimun®), CD66 <sup>5</sup> imaging agent for osteomyelitis (bone infection)				



1. Prostate-specific membrane antigen.  
2. Carbonic anhydrase IX.

3. L-type amino acid transporters 1 and 2.  
4. Brand name subject to final regulatory approval.

5. Cluster of differentiation 66.




# Commercial performance

## Illuccix® increasing share in the growing U.S. market

### Group revenue

AU\$M / US\$M



- Dose volume / demand continues to increase quarter on quarter
- Increased clinical utilisation continues to drive market growth, initial market opportunity for the U.S. estimate increases to **US\$1.5B to US\$2.4B<sup>2</sup>**
- Positive reimbursement reform: CMS<sup>3</sup> final rule to extend separate payments for radiopharmaceutical diagnostics published
- **Full year revenue guidance:** US\$490M to US\$510M (\$745M to \$776M at current exchange rates), representing a ~48-54% increase on 2023



1. ASX disclosure 18 July 2024. Revenue guidance is based on approved products in jurisdictions with a marketing authorisation. Illuccix® has received a marketing authorisation in Australia, Canada and the U.S. Represents full year guidance

2. ACS. Cancer Facts & Figures 2023. Atlanta, GA: American Cancer Society; 2024; Scher 2015, PLoS1; Nezoslosky 2018, J Clinical Oncology; Dinh 2016, Urology. Dollar value based on a price of USD 4,000 per scan.

3. Centers for Medicare & Medicaid Services, a federal agency within the United States Department of Health and Human Services.

# Delivering innovation in PSMA-PET imaging

Maintaining competitive advantage and maximising customer choice

Telix PSMA  
product strategy



TLX007-CDx PSMA  
imaging product



 illuccix<sup>®</sup>  
(kit for the preparation of gallium  
Ga 68 gozetotide Injection)




Choice and confidence  
in PSMA imaging



- **Broadest patient reach in the U.S.** Illuccix + TLX007-CDx will expand geographic coverage to all available PET cameras
- **Addresses inequity in PSMA-PET imaging availability**, access for underserved patient populations
- **Unrivalled production, workflow and dosing flexibility** to produce at large-scale or on-demand, using gallium sourced from generator or cyclotron, powered by ARTMS
- **Customer choice to optimise and address market** segmentation needs tailored to patient profile / indication

**NDA for TLX007-CDx accepted for filing –  
PDUFA goal date 24 March 2025**




*Note: Patient representative sample  
- individual results may vary.*

Credit: BAMF Health.

# Precision medicine presents a near-term growth opportunity

Label expansion studies will facilitate expedited access to expanded market



1. National Comprehensive Cancer Network®.  
 2. American Urological Association.

3. Clear cell renal cell carcinoma.  
 Zircaix and Pixclara brand names subject to final regulatory approval.



# Core therapeutic pipeline

	TARGETING AGENT	ISOTOPE	PRE-CLINICAL	PHASE I	PHASE II	PHASE III	COMMERCIAL
Prostate PSMA <sup>1</sup>	Antibody	<sup>177</sup> Lu	TLX591 ( <sup>177</sup> Lu rosopatamab tetraxetan)				
	Antibody	<sup>225</sup> Ac (alpha)	TLX592 ( <sup>225</sup> Ac-RADmAb®)				
Kidney + other CAIX <sup>2</sup>	Antibody	<sup>177</sup> Lu	TLX250 ( <sup>177</sup> Lu-girentuximab)				
	Antibody	<sup>225</sup> Ac (alpha)	TLX252 ( <sup>225</sup> Ac-girentuximab)				
Brain LAT1 & LAT2 <sup>3</sup>	Small molecule	<sup>131</sup> I	TLX101 ( <sup>131</sup> I-IPA)				
	Small molecule	<sup>211</sup> At (alpha)	TLX102 ( <sup>211</sup> At-APA)				
Musculo- skeletal	Antibody	<sup>90</sup> Y	TLX66 ( <sup>90</sup> Y-besilesomab), CD66 <sup>4</sup> targeting agent for bone-marrow conditioning for haematological diseases				
	Small molecule	<sup>153</sup> Sm	TLX090 ( <sup>153</sup> Sm-DOTMP), bone-seeking agent for bone metastases and pain palliation				
	Antibody	Undisclosed	TLX300 (-olaratumab), PDGFR $\alpha$ <sup>5</sup> targeting radio antibody-drug conjugate for soft-tissue sarcoma (STS) treatment				



1. Prostate-specific membrane antigen.  
2. Carbonic anhydrase IX.


3. L-type amino acid transporters 1 and 2.  
4. Cluster of differentiation 66.

5. Platelet derived growth factor receptor alpha.


# TLX591 ProstACT GLOBAL Phase 3 Study Schema



## Part 1: Dosimetry & Safety Lead-In (n = 30)



## Part 2: Randomized Treatment Expansion (n=490)



**SOC determined by the Investigator:**

- Part 1: Prior to treatment with TLX591
- Part 2: Prior to randomization

Change in planned SOC is not permitted.

**SOC**

- ARPI switch from abiraterone to enzalutamide (or vice versa)
- Docetaxel

**Stratification factors:**

- Chosen SOC (ARPI or docetaxel)
- Disease burden
- Disease setting of first ARPI (mCSPC, 1L mCRPC)



1. Standard of care.  
2. Metastatic castrate-resistant prostate cancer.  
3. Androgen receptor pathway inhibitor.  
4. Metastatic castrate-sensitive prostate cancer.

5. Adverse events/serious adverse events.  
6. Radiographic progression-free survival.  
7. Objective response rate.  
8. Prostate-specific antigen.

9. Overall survival.  
10. Symptomatic skeletal event.  
11. Quality of life.  
12. IDMC safety and futility analysis

# Acquisition: Next-generation, clinically-validated FAP assets


## A promising pan-cancer target with initial focus on bladder cancer

### Next generation of FAP-targeting theranostics

- **Clinically validated** theranostic drug candidates targeting FAP – a highly promising target<sup>1</sup>
- Next-generation compounds with **superior tumour retention** than earlier drug candidates
- Suitable for beta and alpha therapy applications, underpinned by proven precision medicine strategy (Dx imaging)

### Strategic acquisition bolsters Telix's focus in urology

- Initial development program to focus on bladder cancer, which rounds out urology franchise
- Potential as a pan-cancer program complementing Telix's CAIX portfolio across a range of indications




Clinical effect of <sup>177</sup>Lu-based, FAP-targeted therapeutic candidate in-licensed by Telix, in a patient with breast cancer. Response verified by FDG and FAP-targeted PET (shown) using the diagnostic in-licensed by Telix<sup>2</sup>.

# Delivering to our strategy

## Multiple near-term catalysts ahead



Progress late-stage therapeutic pipeline



Advance next generation of alpha theranostics



Expand commercial imaging portfolio



Vertically integrate supply chain

2024

H1 2025

✓ ProstACT SELECT (TLX591) rPFS data

✓ ProstACT GLOBAL recruitment at U.S. sites

✓ CUPID (TLX592) proof-of-concept for alpha therapy

STARLITE-2 (TLX250 + immunotherapy) Phase II readout

✓ IPAX-1 first peer-review publication

✓ ARTMS and IsoTherapeutics acquisitions

Illuccix® Brazil, EU and UK approval decisions

Zircaix®<sup>1</sup> (TLX250-CDx) BLA completion

✓ ZIRCON first peer-review publication

✓ Pixclara®<sup>1</sup> (TLX101-CDx) NDA accepted

✓ TLX101-CDx EAP open in U.S.

TLX300 clinical program commences in soft tissue sarcoma

ProstACT GLOBAL (TLX591) Ph III interim readout

TLX592 alpha therapeutic trial update

IPAX-2 and IPAX-Linz (TLX101) therapy studies readouts

TLX007-CDx PDUFA date 24 March 2025

Pixclara® (TLX101-CDx) PDUFA data 26 April 2025



1. Brand name subject to regulatory approval.

# Contact details:

Kyahn Williamson

SVP Investor Relations and  
Corporate Communication

[kyahn.williamson@telixpharma.com](mailto:kyahn.williamson@telixpharma.com)

